Robin K. Kelley, MD, on Clinical Implications of New Findings in Biliary Tract Cancer on Pembrolizumab, Gemcitabine, and Cisplatin

Posted: Monday, May 1, 2023

Robin K. Kelley, MD, of the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, discusses the impact of new data showing that the addition of the immune checkpoint inhibitor pembrolizumab to standard chemotherapy improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer. (Abstract CT008)

---